Bleb injections ward off orbital tumours

Article

Bleb injections of subconjunctival chemotherapy lower the risk of developing orbital tumours in patients with retinoblastoma.

Bleb injections of subconjunctival chemotherapy lower the risk of developing orbital tumours in patients with retinoblastoma.

Professor Brian Mohney and his team, Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA, completed a non-comparative interventional case series on two patients who presented with bilateral retinoblastoma.

Subconjunctival chemotherapy was administered to both patients to reduce the risk or orbital tumour seeding after intravitreal injection. The outcome measures were ocular toxicity levels and the presence or absence of viable tumour cells at the injection site.

Subconjunctival chemotherapy bleb injections before intravitreal drug delivery seem to reduce the risk of orbital tumour seeding in patients with advanced stage retinoblastoma.

The paper was recently published in the British Journal of Ophthalmology and is available by clicking here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.